Profile data is unavailable for this security.
About the company
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
- Revenue in USD (TTM)196.83m
- Net income in USD-12.82m
- Incorporated2014
- Employees692.00
- LocationCytek Biosciences Inc47215 LAKEVIEW BOULEVARDFREMONT 94538United StatesUSA
- Websitehttps://cytekbio.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerus Corp | 225.97m | -15.96m | 430.28m | 281.00 | -- | 7.00 | -- | 1.90 | -0.0848 | -0.0848 | 1.20 | 0.3201 | 1.12 | 1.99 | 8.35 | 804,163.70 | -7.91 | -20.38 | -12.30 | -31.96 | 60.50 | 61.15 | -7.09 | -25.37 | 1.29 | -1.04 | 0.5772 | -- | 7.78 | 16.51 | 44.20 | -- | -20.50 | -- |
| Standard Biotools Inc | 128.83m | -109.46m | 430.71m | 818.00 | -- | 1.08 | -- | 3.34 | -0.289 | -0.3383 | 0.3399 | 1.04 | 0.211 | 1.97 | 5.27 | 157,490.20 | -17.93 | -29.45 | -22.06 | -35.68 | 47.94 | 50.11 | -84.97 | -79.68 | 4.14 | -- | 0.0008 | -- | 64.03 | 8.27 | -147.67 | -- | 26.98 | -- |
| AngioDynamics, Inc. | 307.31m | -27.71m | 452.15m | 675.00 | -- | 2.59 | -- | 1.47 | -0.6731 | -0.6731 | 7.47 | 4.24 | 1.10 | 2.12 | 7.02 | 455,268.20 | -9.87 | -13.69 | -13.83 | -16.19 | 54.58 | 52.46 | -9.02 | -21.32 | 1.33 | -- | 0.0329 | -- | -3.76 | 2.06 | 81.56 | -- | -10.06 | -- |
| Neuropace Inc | 94.86m | -23.99m | 497.88m | 209.00 | -- | 27.05 | -- | 5.25 | -0.7535 | -0.7535 | 2.98 | 0.5564 | 0.9321 | 1.46 | 7.16 | 515,565.20 | -23.57 | -35.71 | -28.36 | -44.34 | 76.77 | 73.39 | -25.28 | -60.45 | 3.94 | -3.58 | 0.7603 | -- | 22.14 | 16.67 | 17.64 | -- | -8.15 | -- |
| Mesa Laboratories Inc | 247.54m | 3.73m | 500.49m | 730.00 | 140.00 | 2.68 | 17.41 | 2.02 | 0.6471 | 0.6471 | 44.81 | 33.79 | 0.5678 | 3.40 | 6.28 | 339,097.30 | 0.8564 | -8.81 | 1.13 | -9.71 | 62.40 | 61.98 | 1.51 | -25.15 | 1.45 | 1.62 | 0.4709 | -- | 11.47 | 15.41 | 99.22 | -- | 24.60 | 0.00 |
| Pacific Biosciences of California Inc | 160.01m | -546.38m | 516.26m | 575.00 | -- | 96.52 | -- | 3.23 | -1.84 | -1.84 | 0.5335 | 0.0177 | 0.1565 | 1.96 | 5.08 | -- | -53.45 | -22.47 | -59.23 | -24.40 | 33.97 | 33.11 | -341.47 | -214.45 | 2.44 | -19.72 | 0.9918 | -- | 3.89 | 15.19 | -76.34 | -- | -- | -- |
| Anteris Technologies Global Corp | 2.14m | -84.32m | 523.69m | 136.00 | -- | 55.68 | -- | 244.82 | -2.34 | -2.34 | 0.0594 | 0.1025 | 0.1065 | 1.53 | 11.88 | 15,728.75 | -420.16 | -- | -1,527.00 | -- | 67.94 | -- | -3,945.70 | -- | 0.8032 | -- | 0.046 | -- | -1.16 | -- | -65.77 | -- | -- | -- |
| Orthofix Medical Inc | 818.06m | -119.12m | 529.84m | 1.62k | -- | 1.19 | -- | 0.6477 | -3.04 | -3.04 | 20.82 | 11.20 | 0.9622 | 1.37 | 6.40 | 506,224.00 | -14.01 | -10.81 | -17.28 | -13.34 | 68.27 | 70.31 | -14.56 | -11.57 | 1.38 | -1.35 | 0.2837 | -- | 7.08 | 11.69 | 16.78 | -- | 8.75 | -- |
| Cytek Biosciences Inc | 196.83m | -12.82m | 542.15m | 692.00 | -- | 1.43 | -- | 2.75 | -0.1011 | -0.1011 | 1.54 | 2.96 | 0.3992 | 1.86 | 3.60 | 303,746.90 | -2.60 | 0.3407 | -3.02 | 0.3811 | 53.46 | 58.12 | -6.51 | 0.8678 | 4.48 | -- | 0.0213 | -- | 3.85 | 28.20 | 50.44 | -- | 30.83 | -- |
| Varex Imaging Corp | 854.40m | -67.70m | 566.49m | 2.40k | -- | 1.19 | -- | 0.663 | -1.63 | -1.63 | 19.34 | 11.38 | 0.7032 | 1.85 | 6.00 | 356,000.00 | -5.55 | -0.3327 | -6.45 | -0.3955 | 34.15 | 33.16 | -7.89 | -0.4661 | 1.87 | 2.22 | 0.4321 | -- | 4.14 | 2.73 | -47.38 | -- | -0.5159 | -- |
| Tactile Systems Technology Inc | 311.51m | 18.17m | 590.78m | 1.04k | 34.05 | 2.88 | 23.72 | 1.90 | 0.7768 | 0.7768 | 13.28 | 9.18 | 1.14 | 8.38 | 8.07 | 300,398.30 | 6.64 | 1.29 | 7.72 | 1.55 | 49.87 | 49.12 | 5.83 | 1.26 | 3.20 | -- | 0.00 | 0.00 | 6.76 | 9.11 | -40.52 | 9.10 | -15.97 | -- |
| Embecta Corp | 1.08bn | 139.50m | 602.27m | 1.85k | 4.30 | -- | 3.33 | 0.5578 | 2.37 | 2.37 | 18.31 | -10.35 | 0.9757 | 2.27 | 6.35 | 583,621.60 | 12.61 | 16.69 | 16.60 | 22.65 | 63.17 | 66.74 | 12.92 | 15.71 | 1.87 | 3.18 | 1.79 | 13.07 | -3.80 | -0.1033 | 21.84 | -25.93 | -26.03 | -- |
| Beta Bionics Inc | 88.57m | -77.84m | 613.70m | 404.00 | -- | 2.08 | -- | 6.93 | -2.07 | -2.07 | 2.21 | 6.70 | 0.4149 | 2.54 | 8.16 | 304,364.30 | -36.46 | -- | -40.57 | -- | 54.51 | -- | -87.89 | -- | 9.83 | -- | 0.00 | -- | 442.93 | -- | -24.17 | -- | -- | -- |
| Alpha Tau Medical Ltd | 0.00 | -39.97m | 614.75m | 125.00 | -- | 7.92 | -- | -- | -0.5212 | -0.5212 | 0.00 | 0.9099 | 0.00 | -- | -- | 0.00 | -40.90 | -34.28 | -44.43 | -36.47 | -- | -- | -- | -- | -- | -- | 0.0735 | -- | -- | -- | -8.89 | -- | 11.60 | -- |
Data as of Feb 13 2026. Currency figures normalised to Cytek Biosciences Inc's reporting currency: US Dollar USD
46.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 15.86m | 12.40% |
| Topline Capital Management LLCas of 30 Sep 2025 | 6.94m | 5.43% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.74m | 5.27% |
| HHLR Advisors Ltd.as of 30 Sep 2025 | 6.66m | 5.21% |
| Boston Partners Global Investors, Inc.as of 31 Dec 2025 | 5.01m | 3.92% |
| Brown Capital Management LLCas of 30 Sep 2025 | 4.96m | 3.88% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.15m | 3.24% |
| Millennium Management LLCas of 30 Sep 2025 | 3.42m | 2.67% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.79m | 2.18% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.49m | 1.95% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
